BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Trulicity (dulaglutide) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Trulicity (dulaglutide)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07319286-127@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trulicity (dulaglutide): Phase 1/2 readout est. (NCT07319286)
DESCRIPTION:Trulicity (dulaglutide)\, phase 1/2.\nStudy: Role of Glucagon-l
 ike Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent 
 Females With Type 1 Diabetes Mellitus\nEstimated primary completion: Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dulaglutide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073
 19286
URL:https://assetmemo.bio/drug/dulaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07537088-127@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Trulicity (dulaglutide): Phase 4 readout est. (NCT07537088)
DESCRIPTION:Trulicity (dulaglutide)\, phase 4\, Type 2 Diabetes.\nStudy: Ef
 ficacy and Safety of Triple Therapy With Dulaglutide\, SGLT2 Inhibitors\, 
 and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney D
 isease\nEstimated primary completion: April 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/dulaglutide#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07537088
URL:https://assetmemo.bio/drug/dulaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04731272-127@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Trulicity (dulaglutide): Phase 2 readout est. (NCT04731272)
DESCRIPTION:Trulicity (dulaglutide)\, phase 2.\nStudy: GLP-1 Agonist Therap
 y in Cystic Fibrosis-Related Glucose Intolerance\nEstimated primary comple
 tion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 ulaglutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT04731272
URL:https://assetmemo.bio/drug/dulaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06739122-127@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trulicity (dulaglutide): Phase 3 readout est. (NCT06739122)
DESCRIPTION:Trulicity (dulaglutide)\, phase 3\, Type 2 Diabetes.\nStudy: A 
 Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participan
 ts With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)\nEstimated primary comp
 letion: December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/dulaglutide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06739122
URL:https://assetmemo.bio/drug/dulaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05478707-127@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Trulicity (dulaglutide): Phase 2 readout est. (NCT05478707)
DESCRIPTION:Trulicity (dulaglutide)\, phase 2.\nStudy: Therapeutic Strategi
 es for Microvascular Dysfunction in Type 1 Diabetes\nEstimated primary com
 pletion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/dulaglutide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05478707
URL:https://assetmemo.bio/drug/dulaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06324461-127@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trulicity (dulaglutide): Phase 4 readout est. (NCT06324461)
DESCRIPTION:Trulicity (dulaglutide)\, phase 4.\nStudy: GLP-1 Receptor Agoni
 st for Reduction of Myocardial Injury After Non-cardiac Surgery\nEstimated
  primary completion: 31 December 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/dulaglutide#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06324461
URL:https://assetmemo.bio/drug/dulaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282041-127@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Trulicity (dulaglutide): Phase 2/3 readout est. (NCT07282041)
DESCRIPTION:Trulicity (dulaglutide)\, phase 2/3\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: Role of GLP1 RA Dulaglutide on Severe Intracranial 
 Atherosclerosis\nEstimated primary completion: 1 December 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/dulaglutide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07282041
URL:https://assetmemo.bio/drug/dulaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
